DDInter1826 DDInter1766
A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016 and was approved by the FDA in January 2020 for the treatment of TED. Thyroid eye disease is a potentially debilitating complication of Graves' Disease involving inflammation and tissue remodeling behind the eye, and previous treatment options typically involved multiple invasive surgeries - teprotumumab is the first drug ever approved for the treatment of TED and therefore represents a significant step forward in the treatment this disease.
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teprotumumab
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin degludec
Insulin degludec {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teprotumumab
Tolazamide {u} (Compound) resembles {v} (Compound) Glyburide
Glyburide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teprotumumab
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin glulisine
Insulin glulisine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teprotumumab
Tolazamide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teprotumumab
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teprotumumab
Tolazamide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teprotumumab
Tolazamide {u} (Compound) binds {v} (Gene) ABCC8
ABCC8 {u} (Gene) is bound by {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teprotumumab
Tolazamide {u} (Compound) is included by {v} (Pharmacologic Class) Sulfonylurea Compounds
Sulfonylurea Compounds {u} (Pharmacologic Class) includes {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teprotumumab
Tolazamide {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teprotumumab
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Tolazamide (Compound) resembles Glyburide (Compound) and Glyburide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Tolazamide (Compound) resembles Chlorpropamide (Compound) and Chlorpropamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Tolazamide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Tolazamide (Compound) binds ABCC8 (Gene) and ABCC8 (Gene) is bound by Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Tolazamide (Compound) is included by Sulfonylurea Compounds (Pharmacologic Class) and Sulfonylurea Compounds (Pharmacologic Class) includes Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Tolazamide (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab